Arctus Therapeutics (ARCH) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.
ARCH has 8 Form 4 insider filings recorded at the SEC in the past 30 days[1].
Sources
- SEC EDGAR (2026-04-11) ↗
ARCH is tracked by BiotechSigns with a current catalyst score of 93/100 and grade A. The page summarizes 18 active signals, including 0 PDUFA, 1 insider buying, and 1 clinical trial signals, with data refreshed on 2026-06-03.
Arctus Therapeutics (ARCH) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.
ARCH has 8 Form 4 insider filings recorded at the SEC in the past 30 days[1].